Expert Commentary: The Safety of Fibrates in Lipid-Lowering Therapy

American Journal of Cardiology

Volumn 99, Issue 6 SUPPL. 1, 2007, Pages

  Brown, W Virgil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG SAFETY; DRUG USE; HUMAN; HYPERLIPIDEMIA; LUNG EMBOLISM; MYOPATHY; OUTCOME ASSESSMENT; PANCREATITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEINURIA; RETINOPATHY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CLOFIBRIC ACID; DATABASES, FACTUAL; DYSLIPIDEMIAS; EXPERT TESTIMONY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33947104636     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.11.017     Document Type: Article

References (28)

1. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 (1997) 779-791
2. Li A.C., and Glass C.K. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45 (2004) 2161-2173
3. de Gennes J.L., Maunand B., Salmon D., Laudat P., and Truffert J. Results of atromid or CPIB treatment with and without androsterone in hyperlipemia (110 therapeutic trials in 2 years). Bull Mem Soc Med Hop Paris 116 (1965) 759-784
4. Brown W.V. Treatment of hypercholesterolemia with fenofibrate: a review. Curr Med Res Opin 11 (1987) 321-330
5. Brown W.V., Dujovne C.A., Farquhar J.W., Feldman E.B., Grundy S.M., Knopp R.H., Lasser N.L., Mellies M.J., Palmer R.H., Samuel P., Schonfeld G., and Superko H.R. Effects of fenofibrate on plasma lipids: double blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 6 (1986) 678-680
6. Slowe I.A., Carter A.C., and Feldman E.B. Divergent effects in the treatment of hyperlipemia. Arch Intern Med 116 (1965) 523-530
7. Quarfordt S., Levy R.I., and Fredrickson D.S. On the lipoprotein abnormality in type 3 hyperlipoproteinemia. J Clin Invest 50 (1971) 754-761
8. Morganroth J., Levy R.I., and Fredrickson D.S. The biochemical, clinical, and genetic features of Type III hyperlipoproteinemia. Ann Intern Med 82 (1975) 158-174
9. Zelis R., Mason D.T., Braunwald E., and Levy R.I. Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest 49 (1970) 1007-1015
10. Stamler J. The coronary drug project-findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 82 (1977) 52-75
11. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J 40 (1978) 1069-1118
12. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2 (1980) 379-385
13. Heady J.A., Morris J.N., and Oliver M.F. WHO clofibrate/cholesterol trial: clarifications. Lancet 340 (1992) 1405-1406
14. Davidson M.H., Armani A., McKenney J.M., and Jacobson T.A. Safety considerations with fibrate therapy. Am J Cardiol 99 suppl (2007) 3C-18C
15. Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Katianiemi P., Koskinen P., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
16. Grundy S.M., Ahrens Jr. E.H., and Salen G. Mechanism of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 13 (1972) 531-551
17. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
18. Langer T., and Levy R.I. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279 (1968) 856-858
19. McGarvey J.F. Premature contractions and clofibrate. JAMA 225 (1973) 638
20. Tobert J.A. Efficacy and long term adverse effect pattern of lovastatin. Am J Cardiol 62 suppl (1988) 28J-34J
21. Illingworth D.R., and Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 79 (1989) 590-596
22. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
23. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 (2005) 120-122
24. Tsimihodimos V., Kakafika A., and Elisaf M. Fibrate treatment can increase serum creatinine. [letter]. Nephrol Dial Transplant 16 (2001) 1301
25. Tsimihodimos V., Miltiadous G., Bairaktari E., and Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 57 (2002) 407-408
26. Genest J., Frohlich J., and Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol 93 (2004) 848-853
27. Syvanne M., Whittall R.A., Turpeinen U., Nieminen M.S., Frick M.H., Kesaniemi Y.A., Pasternack A., Humphries S.E., and Taskinen M.R. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 172 (2004) 267-272
28. Ansquer J.C., Foucher C., Rattier S., Taskinen M.R., Steiner G., and DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in the placebo-controlled study in type 2 diabetes: results from Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45 (2005) 485-493